Cargando…

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects

β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) is required for the production of β‐amyloid peptides, which are implicated in the etiology of Alzheimer's disease. The safety and pharmacokinetics of the BACE1 inhibitor verubecestat have previously been studied in young adults aged 19–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forman, Mark, Palcza, John, Tseng, Jack, Stone, Julie A., Walker, Brittany, Swearingen, Dennis, Troyer, Matthew D., Dockendorf, Marissa F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742941/ https://www.ncbi.nlm.nih.gov/pubmed/31215755 http://dx.doi.org/10.1111/cts.12645

Ejemplares similares

BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines
por: Blume, Tanja, et al.
Publicado: (2018)

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
por: Egan, Michael F., et al.
Publicado: (2019)

Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice
por: Oblak, Adrian L., et al.
Publicado: (2022)

Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease
por: Zhang, Zhentao, et al.
Publicado: (2015)

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPP(swe) Mice Without Inducing Microhemorrhage
por: Villarreal, Stephanie, et al.
Publicado: (2017)

Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2
por: Yan, Riqiang
Publicado: (2017)

Withdrawal: Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis
por: Puglielli, Luigi, et al.
Publicado: (2022)

Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions
por: Voss, Tiffini, et al.
Publicado: (2023)

Antibacterial and β-amyloid precursor protein-cleaving enzyme 1 inhibitory polyketides from the fungus Aspergillus chevalieri
por: Wang, Qing-Yuan, et al.
Publicado: (2022)

Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer’s disease
por: Evin, Genevieve, et al.
Publicado: (2014)

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage
por: Portelius, Erik, et al.
Publicado: (2014)

Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1-AS expression
por: LIU, TE, et al.
Publicado: (2014)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

Beta-Site Amyloid Precursor Protein-Cleaving Enzyme Inhibition Partly Restores Sevoflurane-Induced Deficits on Synaptic Plasticity and Spine Loss
por: Wang, Xingxing, et al.
Publicado: (2022)

The hammerhead self-cleaving motif as a precursor to complex endonucleolytic ribozymes
por: DasGupta, Saurja, et al.
Publicado: (2021)

Icaritin, an inhibitor of beta-site amyloid cleaving enzyme-1, inhibits secretion of amyloid precursor protein in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway
por: Feng, Fei, et al.
Publicado: (2019)

Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer’s disease patients
por: Kirsebom, Bjørn Eivind, et al.
Publicado: (2022)

Amyloid precursor protein and amyloid precursor-like protein 2 in cancer
por: Pandey, Poomy, et al.
Publicado: (2016)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

The amyloid precursor protein: beyond amyloid
por: Zheng, Hui, et al.
Publicado: (2006)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Soluble Sema4D cleaved from osteoclast precursors by TACE suppresses osteoblastogenesis
por: Ishii, Takenobu, et al.
Publicado: (2023)

Inhibition of β-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure−activity relationship with a strong BBB permeability
por: Jannat, Susoma, et al.
Publicado: (2019)

Interactions between amyloid, amyloid precursor protein, and mitochondria
por: Wilkins, Heather M.
Publicado: (2023)

551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
por: Ankrom, Wendy, et al.
Publicado: (2018)

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
por: Propper, David J., et al.
Publicado: (2022)

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
por: Maccecchini, Maria L, et al.
Publicado: (2012)

Cleaving and migrating
por: Wells, William A.
Publicado: (2001)

Biology and pathophysiology of the amyloid precursor protein
por: Zheng, Hui, et al.
Publicado: (2011)

Amyloid Precursor Protein and Alzheimer’s Disease
por: Orobets, Kseniia S., et al.
Publicado: (2023)

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
por: Ankrom, Wendy, et al.
Publicado: (2020)

MK-STYX Alters the Morphology of Primary Neurons, and Outgrowths in MK-STYX Overexpressing PC-12 Cells Develop a Neuronal Phenotype
por: Banks, Dallas A., et al.
Publicado: (2017)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
por: Yang, Bangkun, et al.
Publicado: (2016)

The Nuclear Inclusion a (NIa) Protease of Turnip Mosaic Virus (TuMV) Cleaves Amyloid-β
por: Han, Hye-Eun, et al.
Publicado: (2010)

Matriptase cleaves the amyloid-beta peptide 1–42 at Arg-5, Lys-16, and Lys-28
por: Chen, Li-Mei, et al.
Publicado: (2019)

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

The acid–base and redox properties of menaquinone MK-4, MK-7, and MK-9 (vitamin K(2)) in DMPC monolayers on mercury
por: Dharmaraj, Karuppasamy, et al.
Publicado: (2020)

Amyloid Precursor Protein (APP) Affects Global Protein Synthesis in Dividing Human Cells
por: Sobol, Anna, et al.
Publicado: (2015)

High Fat Diet Enhances β-Site Cleavage of Amyloid Precursor Protein (APP) via Promoting β-Site APP Cleaving Enzyme 1/Adaptor Protein 2/Clathrin Complex Formation
por: Maesako, Masato, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ils6jk84c5r0pgah3gjcrh0k1e